Can someone please clarify the following for me:1. DMD is touted...

Can someone please clarify the following for me:

1. DMD is touted as having "approximately 300,000 DMD patients worldwide". Why does it state on pg 13 the "total prevalent population is approximately 40,000 DMD patients in US / EU", even though ATL1102 addresses DMD for ambulant, non-ambulant and adults?

2. If this trial is successful and leads to commercialisation, how will this impact the clinical trials for ambulant boys and limb girdle which are both in the pre-clinical stage.

3. DMD for non-ambulant boys, Multiple Sclerosis and Acromegaly are all in phase 2. I am going to assume that phase 2 is not analogous with clinical trial and we don't have any substantial results for these indicators yet?